Диссертация (1140048), страница 17
Текст из файла (страница 17)
Circulation 2004; 1 09: 1 509-13.70. Davis R.C., Hobbs F.D., Roalfe A.K. et al. Plasma brain natriuretic peptideassay is valuable in diagnosis of heart failure in the community, as well as inhospital. Eur Heart J 2000;21:133.71. De Denus S., Sanoski C.A., Carlsson J. et al.
Rate vs rhythm control inpatients with atrial fibrillation: a meta4analysis // Arch. Intern. Med. –2005. – Vol. 165. – P. 258–262.72. De Lemos J. A., McGuire D.K., Drazner M.H. B-type natriuretic peptide incardiovascular disease. Lancet 2003;362:316-322.73. Dernellis J., Panaretou M. Left atrial function in patients with a high C4reactive protein level and paroxysmal atrial fibrillation // Acta Cardiol. –2006. – Vol. 61. – P.
507–511.74. Dries D, Exner D, Gersh B. Atrial fibrillation is associated with an increasedrisk for mortality and heart failure progression in patients with asymptomatic andsymptomatic left ventricular systolic dysfunction: a retrospective analysis of theSOLVD trials. JACC 1998; 32: 695-703.10675.
El Aouar LM, Meyerfreud D, Magalhães P, et al. Relationship between leftatrial volume and diastolic dysfunction in 500 Brazilian patients. Arq BrasCardiol. 2013 Jul;101(1):52-8.76. Frost L., Engholm G., Johnsen S., et al. Incident thromboembolism in the aortaand the renal, mesenteric, pelvic, and extremity arteries after discharge from thehospital with a diagnosis of atrial fibrillation. Arch Intern Med. 2001 Jan22;161(2):272-6.77. Furberg C, Psaty B, Monolio T, et al. Prevalence of atrial fibrillation in elderlysubjects (the Cardiovascular Health Stady).
Am J Cardiol 1994; 74: 236-41.78. Gaita F, Corsinovi L, Anselmino M, Raimondo C et al. Prevalence of silentcerebral ischemia in paroxysmal and persistent atrial fibrillation and correlationwith cognitive function. // J Am Coll Cardiol. 2013 Nov 19;62(21):1990-7.79. Galante O., Amit G., Zahger D., Wagshal A., Ilia R., Katz A. B-typeNatruiretic Peptide Levels Stratifythe Risk for Arrhythmia Among ImplantableCardioverter Defibrillator Patients.// Clin. Cardiol.- 2008.-Vol.31.-P.586-9.80.
Gersh B. J., Tsang T. S. M., Seward J. B. The changing epidemiology andnatural history of non-valvular atrial fibrillation: clinical implication // Trans AmClin Climatol Assoc. 2004; 115: 149–59; discussion 159–160.81. Go A.S., Hylek E.M., Phillips K.A., et al. Prevalence of diagnosed AF inadults: national implications for rhythm management and stroke prevention: theanticoagulation and risk factors in atrial fibrillation (ATRIA) Study.
JAMA 2001;285: 2370-5.82. Gronefeld G.C., Hohnloser S.H. Heart failure complicated by atrial fibrillation:mechanistic, prognostic, and therapeutic implications. // J. Cardiovasc. Pharmacol.Ther., 2003, Jun; Vol. 8(2). Р. 107–113.83. Gronefeld G.C., Lilienthal J., Kuck K.H., Hohnloser S.H.; PharmacologicalIntervention in Atrial Fibrillation (PIAF) Study investigators. Impact of rate versusrhythm control on quality of life in patients with persistent atrial fibrillation.Results from a prospective randomized study.
Eur Heart J. 2003 Aug;24(15):14306.10784.Haaf P., Reichlin T., Corson N., Twerenbold R., et al. B-type natriureticpeptide in the early diagnosis and risk stratification of acute chest pain. Am JMed. 2011 May;124(5):444-52.85. Hagens V., Hagens E., Vermeulen K. et al. Rate control was more costeffective than rhythm control for patients with persistent atrial fibrillation – resultsfrom the Rate Control versus Electrical cardioversion (RACE) study // Eur.
HeartJ. – 2004. – Vol. 25. – P. 1542–1549.86. Hailong Caoa, Lei Xuea, Yanhu Wua, et al. Natriuretic peptides and right atrialfibrosis in patients with paroxysmal versus persistent atrial fibrillation. Peptides 31(2010) 1531-1539.87. Hajsadeghi S., Kashani Amin L., Bakhshandeh H., et al. The diagnostic valueof N-terminal pro-brain natriuretic peptide in differentiating cardioembolicischemic stroke. J Stroke Cerebrovasc Dis. 2013 May;22(4):554-60.88. Hans-Ruprecht Neuberger, Christian Mewis, Dirk J., et al. Management ofatrial fibrillation with heart failure.
Europ Heart J//2007; 28: 2568-2577.89. Hildebrandt P., Boesen M., Olsen M. N-terminal pro brain natriuretic peptidein arterial hypertension a marker for left ventricular dimensions and prognosis. EurJ Heart Fail 2004;6:313-317.90. Hohnloser S.H., Kuck K.H., Lilienthal J. Rhythm or rate control in atrialfibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): arandomised trial. Lancet 2000;356:1789—1794.91.
Hohnloser S.H., Pajitnev D., Pogue J., et al Incidence of stroke in paroxysmalversus sustained atrial fibrillation in patients taking oral anticoagulation orcombined antiplatelet therapy: an ACTIVE W Substudy// J Am. Coll. Cardiol. –2007 – Vol. 50 – P.2156 – 2161.92. Hsu L.F., Jais P., Sanders P., et al.
Catheter ablation for atrial fibrillation incongestive heart failure. N Engl J Med 2004; 351: 2373–2383.93. Hu R.M., Levin E.R., Pedram A., Frank H.J.L. I. Atrial tutriuretic peptideinhibits the production and secretion of endothelin from cultured endothelial cellsmediation through the C receptor. J Biol Chem 1992;267:17384-17389.10894. Ionescu-Ittu R., Abrahamowicz M., Jack evicius C. A. et al.
Comparativeeffectiveness of rhythm control vs rate control drug treatment effect on mortality inpatients with atrial fibrillation. Arch Intern Mec 2012; 172: 997-1 004.95. Jenkins LS, Brodsky M, Schron E et al. Quality of life in atrial fibrillation: theAtrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)study. // Am. Heart J., 2005, Jan, vol 149(1), p.112-120.96. Jouven X., Desnos M., Guerot C. et al. Idiopatic atrial fibrillation as a riskfactor for mortality. The Paris Prospective Study I // Eur.
Heart J. – 1999. –Vol.20. – p.896-899.97. Kamkin A., Kiseleva I.,Wagner K.D. et.al. Machanelectric feedback in rightatrium after ventricular in arction in rats // J. Mol. Cell. Cardiol. 2000. - Vol.3. - P.465-477.98. Kazanegra R., Van Cheng, Garcia A., et al A rapid test for B-type natriureticpeptide correlates with filling wedge pressure in patients treated fordecompensated heart failure: a pilot study. // J. Car. Fail. — 2001. -№ 7.-P. 21-29.99.
Khan, I. A. Atrial stunning: determinants and cellular mechanisms //Am. HeartJ. 2003. - Vol. 145. - P. 787-94.100. Khan M.N., Jais P., Cummings J., et al. Pulmonary-vein isolation for atrialfibrillation in patients with heart failure. N Engl J Med 2008; 359: 1778–1785.101. Khand A.U., Chew P.G., Douglas H., et al. The effect of carvedilol on B-typenatriuretic Peptide and cardiac function in patients with heart failure and persistentatrial fibrillation. Cardiology.
2015;130(3):153-8.102. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrialfibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-upStudy. Am J Med. 1995; 98: 476-84.103. Kostin S., Klein G., Szalay Z., Hein S., Bauer E.P., Schaper J. Structuralcorrelate of atrial fibrillation in human patients. // Cardiovasc Res. 2002 May; Vol.54(2). Р. 361–379.109104. Kosiuk J., Van Belle Y., Bode K., et al.Left ventricular diastolicdysfunction in atrial fibrillation: predictors and relation with symptom severity. JCardiovasc Electrophysiol.
2012 Oct; 23(10): 1073-7.105. Kotur-Stevuljevic J., Memon L., Stefanovic A. et al. Correlation of oxidativestress parameters and inflammatory markers in coronary artery diseasepatients // Clin. Biochem. – 2007. – Vol. 40. – P. 181–187.106. Krauser D.G., Lloyd-Jones D.M., Chae C.U., et al. Effect of body mass indexon natriuretic peptide levels in patients with acute congestive heart failure: aProBNP Investigation of Dyspnea in the Emergency Department (PRIDE)substudy. Am Heart J. 2005 Apr;149(4):744-50.107. Kremastinos D.T., Hamodraka E., Parissis J., et al. Predictive value of B-typenatriuretic peptides in detecting latent left ventricular diastolic dysfunction in betathalassemia major. Am Heart J. 2010 Jan;159(1):68-74.108.
Krim S.R., Vivo R.P., de Lemos J.A. B-type natriuretic peptidesin acute coronary syndromes:implicationsinanagingpopulation.ClinCardiol. 2012 Nov;35(11):682-5.109. Kunisek J., Zaputović L., Mavrić Z., et al. Influence of the type and degree ofleft ventricular hypertrophy on the prevalence of ventricular arrhythmias inpatients with hypertensive heart disease. Med Klin (Munich). 2008 Oct15;103(10):705-11.110. Kurosaki K., Tada H., Hashimoto T., et al. Plasma natriuretic peptideconcentrations as a predictor for successful catheter ablation in patients with drugrefractory atrial fibrillation.
Circ J. 2007 Mar;71(3):313-20.111. Kurosaki K., Hiroshi Tada, Tohru Hashimoto, Plasma natriuretic peptideconcentrations as a predictor for successful catheter ablation in patients with drugrefractory atrial fibrillation. Circ J 2007; 71: 313 – 320.112. Lee J.S., Shim C.Y., Wi J., Joung B., et al. Left ventricular diastolic functionis closely associated with mechanical function of the left atrium in patients withparoxysmal atrial fibrillation.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
